Us Fedratinib Market Size By Applications, By Type, By End-User, By Deployment & By Technology 2032
Fedratinib Market was valued at USD 2.5 Billion in 2022 and is projected to reach USD 4.8 Billion by 2030, growing at a CAGR of 9.2% from 2024 to 2030.
Fedratinib, marketed under the brand name Inrebic, is an oral medication approved by the U.S. Food and Drug Administration (FDA) on August 16, 2019, for the treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis (MF). Myelofibrosis is a type of myeloproliferative neoplasm characterized by the scarring of bone marrow, leading to severe anemia, fatigue, and splenomegaly. Fedratinib functions as a semi-selective inhibitor of Janus kinase 2 (JAK2), a protein involved in the signaling pathways that drive the proliferation of malignant cells in MF. By inhibiting JAK2, fedratinib helps to reduce spleen size and alleviate symptoms associated with the disease.
The approval of fedratinib was based on the results of the JAKARTA trial, a double-blind, randomized, placebo-controlled study involving 289 patients with intermediate-2 or high-risk MF. The primary endpoint was the proportion of patients achieving a ≥35% reduction in spleen volume at the end of cycle 6. Results showed that 37% of patients receiving the recommended dose of 400 mg of fedratinib achieved this reduction, compared to only 1% in the placebo group. Additionally, 40% of patients on fedratinib experienced a ≥50% reduction in myelofibrosis-related symptoms, highlighting its efficacy in symptom management.
Despite its benefits, fedratinib carries a boxed warning regarding the risk of serious and potentially fatal encephalopathy, including Wernicke’s encephalopathy. Healthcare professionals are advised to assess thiamine levels in all patients prior to starting fedratinib and periodically during treatment. If encephalopathy is suspected, fedratinib should be immediately discontinued, and parenteral thiamine initiated. The most common adverse reactions (≥20%) in patients who received fedratinib were diarrhea, nausea, anemia, and vomiting.
In the United States, fedratinib is indicated for the treatment of adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. It is available in the form of fedratinib hydrochloride capsules that are taken by mouth. Patients are typically started on a dose of 400 mg once daily, with adjustments made based on individual tolerance and response.
In summary, fedratinib represents a significant advancement in the treatment of myelofibrosis, offering patients an effective option for managing this challenging condition. Its approval provides an alternative for those who may not respond to or tolerate other therapies, such as ruxolitinib. However, due to the potential for serious side effects, careful patient selection and monitoring are essential to ensure its safe and effective use.
Get an In-Depth Research Analysis of the Global Fedratinib Market Size And Forecast [2025-2032]
Santa Cruz Biotechnology
Cayman Chemical
Adooq Bioscience
BioVision
APExBIO Technology
Selleck Chemicals
AbMole
BOC Sciences
TargetMol
Toronto Research Chemicals
MyBiosource
Aladdin
LifeSpan BioSciences
Taiclone
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Fedratinib Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Fedratinib Market
Age Group
Gender
Ethnicity
Primary Myelofibrosis
Post-Polycythemia Vera Myelofibrosis
Post-Essential Thrombocythemia Myelofibrosis
Previous Treatments
Stage of Disease
Type of Institution
Specialty
Provider Experience
Mode of Administration
Treatment Setting
Frequency of Administration
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Fedratinib Market Research Analysis
1. Introduction of the Global Fedratinib Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Fedratinib Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Fedratinib Market, By Type
6. Global Fedratinib Market, By Application
7. Global Fedratinib Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Fedratinib Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/